Integrins as attractive targets for cancer therapeutics

作     者：Meng Li Ying Wang Mengwei Li Xuezhen Wu Sarra Setrerrahmane Hanmei Xu Meng Li;Ying Wang;Mengwei Li;Xuezhen Wu;Sarra Setrerrahmane;Hanmei Xu

作者机构：National Institutes for Food and Drug ControlBeijing 102629China State Key Laboratory of Natural MedicinesMinistry of Educationthe Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu ProvinceDepartment of Marine PharmacyChina Pharmaceutical UniversityNanjing 211198ChinaAffiliated Hospital of Chifeng CollegeInner Mongolia Autonomous Region 024005China 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2021年第11卷第9期

页      面：2726-2737页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 100602[医学-中西医结合临床] 10[医学] 

基　　金：supported by the National Major Scientific and Technological Special Project for“Significant New Drugs Development”(2018ZX09101001-003)in China 

主　　题：Integrins Extracellular matrix Tumor progression Targeted drug Antagonists Clinical trial 

摘      要：Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological *** molecules facilitate cell-extracellular matrix and cell-cell interactions,and they have been implicated in fibrosis,inflammation,thrombosis,and tumor *** role of integrins in tumor progression makes them promising targets for cancer treatment,and certain integrin antagonists,such as antibodies and synthetic peptides,have been effectively utilized in the clinic for cancer ***,we discuss the evidence and knowledge on the contribution of integrins to cancer ***,we summarize the clinical attempts targeting this family in anti-cancer therapy development.